OSTEOPORE LIMITED — Capital/Financing Update 2020

Aug 27, 2020

==> picture [130 x 44] intentionally omitted <==

ASX RELEASE│OSTEOPORE LIMITED

COMPLETION OF PLACEMENT AND CLEANSING NOTICE

28 August 2020: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”) wishes to advise that further to the ASX announcement on 21 August 2020, the Company has today issued 16,037,736 fully paid ordinary shares at $0.53 each to institutional and sophisticated investors.

The 16,037,736 shares were issued using the Company’s existing placement capacity available under 7.1 and 7.1A of the ASX Listing Rules, with 12,184,575 fully paid ordinary shares issued under Listing Rule 7.1 and 3,853,161 fully paid ordinary shares issued under Listing Rule 7.1A.

For the purposes of section 708A(6) of the Corporations Act, the Company gives notice under section 708A(5)(e) of the Corporations Act as follows:

• a) the Company issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act;

• b) as at the date of this notice the Company has complied with:

  • i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

  • ii) section 674 of the Corporations Act; and

• c) as at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act.

This announcement has been approved for release by the Board of Osteopore.

For more information please contact:

Geoff Pocock Executive Director Osteopore Limited +61 4 1219 4373 geoff_pocock@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro‐structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent protected scaffolds are made from proprietary polymer formulations, that naturally dissolve overtime to leave only natural. healthy bone tissue, significantly reducing post‐ surgery complications that are commonly associated with permanent bone implants.

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com